CY1120187T1 - Διαλυματα σιλδεναφιλης και μεθοδοι παρασκευης και χρησης αυτης - Google Patents
Διαλυματα σιλδεναφιλης και μεθοδοι παρασκευης και χρησης αυτηςInfo
- Publication number
- CY1120187T1 CY1120187T1 CY20181100459T CY181100459T CY1120187T1 CY 1120187 T1 CY1120187 T1 CY 1120187T1 CY 20181100459 T CY20181100459 T CY 20181100459T CY 181100459 T CY181100459 T CY 181100459T CY 1120187 T1 CY1120187 T1 CY 1120187T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- sildenafil citrate
- preparation
- sildenafil
- solutions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q1/00—Details of, or arrangements associated with, antennas
- H01Q1/27—Adaptation for use in or on movable bodies
- H01Q1/28—Adaptation for use in or on aircraft, missiles, satellites, or balloons
- H01Q1/288—Satellite antennas
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q1/00—Details of, or arrangements associated with, antennas
- H01Q1/36—Structural form of radiating elements, e.g. cone, spiral, umbrella; Particular materials used therewith
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q5/00—Arrangements for simultaneous operation of antennas on two or more different wavebands, e.g. dual-band or multi-band arrangements
- H01Q5/50—Feeding or matching arrangements for broad-band or multi-band operation
- H01Q5/55—Feeding or matching arrangements for broad-band or multi-band operation for horn or waveguide antennas
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Astronomy & Astrophysics (AREA)
- General Physics & Mathematics (AREA)
- Remote Sensing (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Aviation & Aerospace Engineering (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η εφεύρεση αναφέρεται σε συνθέσεις που περιέχουν διαλυμένο κιτρικό άλας σιλδεναφίλης και σε μεθόδους παραγωγής τέτοιων συνθέσεων, όπου το κιτρικό άλας σιλδεναφίλης διαλύεται σε νερό αναμεμειγμένο με μία ή περισσότερες αλκοόλες και προαιρετικά μπορεί να χρησιμοποιηθεί μια κετόνη για την αύξηση της διαλυτότητας. Επίσης αναφέρεται σε μεθόδους χρήσης τέτοιων συνθέσεων που περιέχουν διαλυμένο κιτρικό άλας σιλδεναφίλης χρησιμοποιώντας δόσεις σημαντικά κάτω από τις υπάρχουσες θεραπευτικές δοσολογίες κιτρικού άλατος σιλδεναφίλης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461955299P | 2014-03-19 | 2014-03-19 | |
PCT/IB2015/052014 WO2015140748A2 (en) | 2014-03-19 | 2015-03-19 | Sildenafil solutions and methods of making and using same |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120187T1 true CY1120187T1 (el) | 2018-12-12 |
Family
ID=54145440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100459T CY1120187T1 (el) | 2014-03-19 | 2018-05-03 | Διαλυματα σιλδεναφιλης και μεθοδοι παρασκευης και χρησης αυτης |
Country Status (24)
Country | Link |
---|---|
US (2) | US9968609B2 (el) |
EP (2) | EP3372083A1 (el) |
JP (1) | JP6744821B2 (el) |
KR (1) | KR20160137584A (el) |
CN (1) | CN106132204B (el) |
AU (2) | AU2015233006B2 (el) |
CA (1) | CA2942628C (el) |
CL (1) | CL2016002318A1 (el) |
CY (1) | CY1120187T1 (el) |
DK (1) | DK3119201T3 (el) |
EA (1) | EA032819B1 (el) |
ES (1) | ES2668915T3 (el) |
HR (1) | HRP20180773T1 (el) |
HU (1) | HUE038431T2 (el) |
IL (1) | IL247840B (el) |
LT (1) | LT3119201T (el) |
MX (1) | MX371276B (el) |
NO (1) | NO2723977T3 (el) |
PL (1) | PL3119201T3 (el) |
PT (1) | PT3119201T (el) |
RS (1) | RS57206B1 (el) |
SG (2) | SG11201607507VA (el) |
SI (1) | SI3119201T1 (el) |
WO (1) | WO2015140748A2 (el) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2723977T3 (el) | 2014-03-19 | 2018-03-10 | ||
JP6902372B2 (ja) * | 2017-02-28 | 2021-07-14 | ヱスビー食品株式会社 | 苦味抑制用組成物 |
AU2018397436A1 (en) * | 2017-12-26 | 2020-08-13 | Ftf Pharma Private Limited | Liquid oral formulations for PDE V inhibitors |
EP3956024A4 (en) * | 2019-04-18 | 2023-01-11 | Ellamed IP & Services Pte. Ltd. | SILDENAFIL CITRATE LIQUID COMPOSITIONS |
AU2020382492A1 (en) * | 2019-11-12 | 2022-05-26 | American Regent, Inc. | Type V phosphodiesterase inhibitor compositions, methods of making them and methods of using them |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017675A1 (en) * | 1993-02-05 | 1994-08-18 | Kao Corporation | Taste modifying method and bitter taste reducing method |
US5785984A (en) * | 1993-02-05 | 1998-07-28 | Kao Corporation | Taste-modifying method and bitterness-decreasing method |
US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
US6531114B1 (en) | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
CA2391968A1 (en) * | 1999-11-18 | 2001-05-25 | Natco Pharma Limited | An improved pharmaceutical composition for treating male erectile dysfunction |
CA2406930C (en) | 2000-02-04 | 2011-02-15 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
WO2002005820A1 (en) | 2000-07-19 | 2002-01-24 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
US20030216407A1 (en) | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
US7611728B2 (en) | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
US20070065394A1 (en) | 2003-11-17 | 2007-03-22 | Pinney Virginia R | Compositions effective in altering the perception of malodor |
ATE387203T1 (de) | 2004-01-05 | 2008-03-15 | Teva Pharma | Prozesse zur herstellung von sildenafil-base und zitratsalz |
CN1925860A (zh) * | 2004-01-05 | 2007-03-07 | 特瓦制药工业有限公司 | 制备西地那非碱及其柠檬酸盐的方法 |
US7727565B2 (en) | 2004-08-25 | 2010-06-01 | Cadbury Adams Usa Llc | Liquid-filled chewing gum composition |
ES2434944T5 (es) | 2005-03-14 | 2022-10-20 | Wyeth Llc | Composiciones de tigeciclina y procedimientos de preparación |
US7556487B2 (en) | 2006-03-29 | 2009-07-07 | Intergum Gida Sinayi ve Ticaret A.S. | Apparatus for making center-filled chewing gum pieces |
FR2906140B1 (fr) * | 2006-09-22 | 2008-12-05 | Philippe Perovitch | Forme galenique pour l'administration par voie trans-muqueuse de principes actifs |
DE502008002360D1 (de) | 2007-06-19 | 2011-03-03 | Symrise Ag | Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck |
EP2072044A1 (en) * | 2007-12-19 | 2009-06-24 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising a liquid or flowable core composition |
WO2009125415A1 (en) | 2008-04-07 | 2009-10-15 | Hetero Research Foundation | Amorphous form of sildenafil citrate |
FR2939321B1 (fr) | 2008-12-05 | 2011-08-26 | Philippe Perovitch | Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique. |
US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
DE102010049708A1 (de) * | 2010-10-28 | 2012-05-03 | Hexal Ag | Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe |
JP6047174B2 (ja) * | 2011-12-05 | 2016-12-21 | スダ リミテッド | シルデナフィルの経口スプレー製剤及びその投与方法 |
GB2497933B (en) | 2011-12-21 | 2014-12-24 | Londonpharma Ltd | Drug delivery technology |
WO2013170655A1 (en) * | 2012-05-16 | 2013-11-21 | Techfields Pharma Co., Ltd. | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
WO2014151729A1 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
NO2723977T3 (el) | 2014-03-19 | 2018-03-10 |
-
2012
- 2012-04-16 NO NO12802846A patent/NO2723977T3/no unknown
-
2015
- 2015-03-19 DK DK15764710.8T patent/DK3119201T3/en active
- 2015-03-19 CN CN201580013951.5A patent/CN106132204B/zh not_active Expired - Fee Related
- 2015-03-19 SG SG11201607507VA patent/SG11201607507VA/en unknown
- 2015-03-19 PT PT157647108T patent/PT3119201T/pt unknown
- 2015-03-19 MX MX2016012154A patent/MX371276B/es active IP Right Grant
- 2015-03-19 KR KR1020167029017A patent/KR20160137584A/ko not_active Application Discontinuation
- 2015-03-19 RS RS20180533A patent/RS57206B1/sr unknown
- 2015-03-19 SG SG10201808038TA patent/SG10201808038TA/en unknown
- 2015-03-19 JP JP2016558141A patent/JP6744821B2/ja not_active Expired - Fee Related
- 2015-03-19 EA EA201691871A patent/EA032819B1/ru unknown
- 2015-03-19 EP EP18161634.3A patent/EP3372083A1/en not_active Withdrawn
- 2015-03-19 PL PL15764710T patent/PL3119201T3/pl unknown
- 2015-03-19 EP EP15764710.8A patent/EP3119201B1/en active Active
- 2015-03-19 HU HUE15764710A patent/HUE038431T2/hu unknown
- 2015-03-19 ES ES15764710.8T patent/ES2668915T3/es active Active
- 2015-03-19 LT LTEP15764710.8T patent/LT3119201T/lt unknown
- 2015-03-19 WO PCT/IB2015/052014 patent/WO2015140748A2/en active Application Filing
- 2015-03-19 AU AU2015233006A patent/AU2015233006B2/en not_active Ceased
- 2015-03-19 CA CA2942628A patent/CA2942628C/en active Active
- 2015-03-19 SI SI201530249T patent/SI3119201T1/en unknown
-
2016
- 2016-09-14 CL CL2016002318A patent/CL2016002318A1/es unknown
- 2016-09-15 US US15/265,897 patent/US9968609B2/en not_active Expired - Fee Related
- 2016-09-15 IL IL247840A patent/IL247840B/en active IP Right Grant
-
2018
- 2018-04-12 US US15/951,197 patent/US10211534B2/en active Active
- 2018-05-03 CY CY20181100459T patent/CY1120187T1/el unknown
- 2018-05-17 HR HRP20180773TT patent/HRP20180773T1/hr unknown
- 2018-10-16 AU AU2018250378A patent/AU2018250378B2/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120187T1 (el) | Διαλυματα σιλδεναφιλης και μεθοδοι παρασκευης και χρησης αυτης | |
CL2017002728A1 (es) | Método para el tratamiento de cáncer | |
CO2017012268A2 (es) | Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2018003597A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
CL2016002517A1 (es) | Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica. | |
CL2017002241A1 (es) | Método de tratamiento de cáncer asociado con una mutación de ras | |
CL2017000806A1 (es) | Compuestos anti-tnf | |
GT201600010A (es) | Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
DOP2015000227A (es) | Virus de la enfermedad de newcastle y usos de los mismos | |
EA201790398A1 (ru) | Способы лечения заболевания печени | |
EA201691579A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
EA202090183A1 (ru) | Композиции, способы и получение дейтерированного домперидона | |
EA201892802A1 (ru) | Производные аденозина для применения при лечении рака | |
SV2017005412A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
CL2016002073A1 (es) | Proceso para producir una solución inyectable de noradrenalina de baja concentración estable | |
CY1122763T1 (el) | Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων | |
CL2017000391A1 (es) | Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea | |
BR112017008481A2 (pt) | composto antimicótico | |
ES2601137T3 (es) | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido | |
ECSP17029203A (es) | Inhibidor de cinasa aurora a | |
BR112017009265A2 (pt) | apilimode para uso no tratamento do câncer colorretal | |
ECSP17015154A (es) | Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo | |
EA201891664A1 (ru) | Составы/композиции, содержащие ингибитор btk | |
ECSP16096831A (es) | Derivados de naftiridinadiona |